- BVD2-21C11 (See other available formats)
- Other Names
- Granulocyte/macrophage colony-stimulating factor, CSF-α, Pluripoietin-α, Eosinophil colony stimulating factor (Eo-CSF), Burst promoting activity (BPA)
- Rat IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
Granulocyte/macrophage - colony stimulating factor (GM-CSF) is a hematopoietic factor that is produced by activated T cells, B cells, mast cells, macrophages, fibroblasts, and endothelial cells. In addition to supporting colony formation of granulocyte/macrophage progenitors, GM-CSF is a growth factor for erythroid, megakaryocyte, and eosinophil progenitors.Product Details
- Human, Cross-Reactivity: Cynomolgus, Rhesus
- Antibody Type
- Host Species
- E. coli-expressed, recombinant human GM-CSF.
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.
- The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. Please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Neut - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by neutralization of the proliferation induced by recombinant human GM-CSF (0.3 ng/mL) on TF-1 human erythroleukemia cells. ND50 range: 0.1 - 0.8 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
Additional reported applications (for the relevant formats) include: ELISA1-4 or ELISPOT3,4 Detection, Neutralization1, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated5,6 and acetone-fixed7 frozen tissue sections, and immunocytochemistry.
Note: For testing human GM-CSF in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 432001 to 432006) are specially developed and recommended.
(PubMed link indicates BioLegend citation)
- Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut, IP)
- Abrams J, et al. 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker New York. p.133. (ELISA)
- Bacchetta R, et al. 1990. J. Immunol. 144:902. (ELISA)
- Kita H, et al. 1991. J. Exp. Med. 174:745. (ELISA)
- Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
- Andersson J, et al. 1994. Immunology 83:16. (IHC)
- Rasouli J, et al. 2015. J. Immunol. 11:5085-93. (IHC)
AB_2814393 (BioLegend Cat. No. 502319)
AB_2814394 (BioLegend Cat. No. 502320)
- Cytokine; 22 kD (Mammalian)
- Growth/development factor for granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors
- Cell Sources
- T cells, macrophages, fibroblasts, endothelial cells, mast cells
- Cell Targets
- Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts
- Heterodimer GM-CSFR α subunit (CDw116); β-subunit (CDw131), which is also shared with the IL-3 and IL-5 receptor α chains
- Biology Area
- Cell Biology, Stem Cells
- Molecular Family
- Cytokines/Chemokines, Growth Factors
- Antigen References
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Demetri G, et al. 1991. Blood 78:2791.
3. Fan D, et al. 1991. In vivo 5:571.
4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.
- Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans
- Gene ID
- 1437 View all products for this Gene ID
- View information about GM-CSF on UniProt.org
- Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
- Do you guarantee that your antibodies are totally pathogen free?
BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
- Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
No, BioLegend does not test for pathogens in-house unless otherwise indicated. However, we can recommend an outside vendor to perform this testing as needed.
- Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.